golimumab,celecoxib
janssen,Pfizer 
['golimumab']
proft et al. nsaids+golimumab no better than golimumab monotherapy in reducing spinal progression in as. but... for high risk patients there may be some benefit - see figure. #acr22 abstr#0546 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC